 Clovis Oncology Inc NASDAQ: CLVS is trading higher Thursday morning after the company announced data from the monotherapy arm of the ATHENA trial achieved the primary endpoint of significantly improved investigator-assessed progression-free survival compared with the placebo. Based on the. 